DMK Pharmaceuticals regains full rights to commercialize Zimhi (naloxone)

DMK is now actively seeking commercialization opportunities for Zimhi in the United States, Canada, and Europe, focused on new, near-term revenues. In the United States, first responders are the primary target for Zimhi, where market data demonstrates significant, unmet demand.

Eboo Versi, M.D., Ph.D., DMK’s CEO commented, “I believe that Zimhi is the ideal product for first responders because it acts so quickly to get patients breathing again to prevent death or prolonged hospitalization especially when faced with a fentanyl overdose. DMK is excited to engage with partners in the United States and abroad to drive long-term growth through new commercialization pathways. We will continue to execute an ambitious operating plan in the United States and expand our business relationships outside of the United States to maximize benefits to patients and DMK’s stakeholders, providing optimal shareholder value.”